136 related articles for article (PubMed ID: 31511286)
1. Is the risk of cervical atypia associated with the interval between menarche and the start of sexual activity? A population-based cohort study.
Adhikari I; Eriksson T; Luostarinen T; Apter D; Lehtinen M
BMJ Open; 2019 Sep; 9(9):e030091. PubMed ID: 31511286
[TBL] [Abstract][Full Text] [Related]
2. The risk of cervical atypia in oral contraceptive users.
Adhikari I; Eriksson T; Luostarinen T; Lehtinen M; Apter D
Eur J Contracept Reprod Health Care; 2018 Feb; 23(1):12-17. PubMed ID: 29412045
[TBL] [Abstract][Full Text] [Related]
3. Proximity of first sexual intercourse to menarche and risk of high-grade cervical disease.
Ruiz ÁM; Ruiz JE; Gavilanes AV; Eriksson T; Lehtinen M; Pérez G; Sings HL; James MK; Haupt RM;
J Infect Dis; 2012 Dec; 206(12):1887-96. PubMed ID: 23066159
[TBL] [Abstract][Full Text] [Related]
4. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
5. Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial.
Castellsagué X; Paavonen J; Jaisamrarn U; Wheeler CM; Skinner SR; Lehtinen M; Naud P; Chow SN; Del Rosario-Raymundo MR; Teixeira JC; Palmroth J; de Carvalho NS; Germar MJ; Peters K; Garland SM; Szarewski A; Poppe WA; Romanowski B; Schwarz TF; Tjalma WA; Bosch FX; Bozonnat MC; Struyf F; Dubin G; Rosillon D; Baril L;
BMC Infect Dis; 2014 Oct; 14():551. PubMed ID: 25927224
[TBL] [Abstract][Full Text] [Related]
6. Association of
Adhikari I; Eriksson T; Harjula K; Hokkanen M; Apter D; Nieminen P; Luostarinen T; Lehtinen M
BMJ Open; 2022 Jun; 12(6):e056824. PubMed ID: 35649600
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial.
Roset Bahmanyar E; Paavonen J; Naud P; Salmerón J; Chow SN; Apter D; Kitchener H; Castellsagué X; Teixeira JC; Skinner SR; Jaisamrarn U; Limson GA; Garland SM; Szarewski A; Romanowski B; Aoki F; Schwarz TF; Poppe WA; De Carvalho NS; Harper DM; Bosch FX; Raillard A; Descamps D; Struyf F; Lehtinen M; Dubin G;
Gynecol Oncol; 2012 Dec; 127(3):440-50. PubMed ID: 22940493
[TBL] [Abstract][Full Text] [Related]
9. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
10. Genetic damage in exfoliated cells of the uterine cervix. Association and interaction between cigarette smoking and progression to malignant transformation?
Cerqueira EM; Santoro CL; Donozo NF; Freitas BA; Pereira CA; Bevilacqua RG; Machado-Santelli GM
Acta Cytol; 1998; 42(3):639-49. PubMed ID: 9622681
[TBL] [Abstract][Full Text] [Related]
11. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors.
Syrjänen K
Eur J Gynaecol Oncol; 2008; 29(3):205-21. PubMed ID: 18592782
[TBL] [Abstract][Full Text] [Related]
12. Effects of oral contraceptives in vaginal cytology.
Montes MB; Ferreira AC; Fenólio JC; Franceschini SA; Toloi MR
Pathologica; 2000 Jun; 92(3):185-8. PubMed ID: 10902429
[TBL] [Abstract][Full Text] [Related]
13. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
14. Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women.
Baldur-Felskov B; Dehlendorff C; Munk C; Kjaer SK
J Natl Cancer Inst; 2014 Mar; 106(3):djt460. PubMed ID: 24552678
[TBL] [Abstract][Full Text] [Related]
15. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial.
Zhao FH; Zhu FC; Chen W; Li J; Hu YM; Hong Y; Zhang YJ; Pan QJ; Zhu JH; Zhang X; Chen Y; Tang H; Zhang H; Durand C; Datta SK; Struyf F; Bi D;
Int J Cancer; 2014 Dec; 135(11):2604-11. PubMed ID: 24740547
[TBL] [Abstract][Full Text] [Related]
16. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Wheeler CM; Castellsagué X; Garland SM; Szarewski A; Paavonen J; Naud P; Salmerón J; Chow SN; Apter D; Kitchener H; Teixeira JC; Skinner SR; Jaisamrarn U; Limson G; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Harper DM; Huh W; Hardt K; Zahaf T; Descamps D; Struyf F; Dubin G; Lehtinen M;
Lancet Oncol; 2012 Jan; 13(1):100-10. PubMed ID: 22075170
[TBL] [Abstract][Full Text] [Related]
17. Young women, cervical intraepithelial neoplasia and human papillomavirus: risk factors for persistence and recurrence.
Frega A; Stentella P; De Ioris A; Piazze JJ; Fambrini M; Marchionni M; Cosmi EV
Cancer Lett; 2003 Jul; 196(2):127-34. PubMed ID: 12860270
[TBL] [Abstract][Full Text] [Related]
18. Age at menarche is not an independent risk factor for high-risk human papillomavirus infections and cervical intraepithelial neoplasia.
Syrjänen K; Shabalova I; Petrovichev N; Kozachenko V; Zakharova T; Pajanidi J; Podistov J; Chemeris G; Sozaeva L; Lipova E; Tsidaeva I; Ivanchenko O; Pshepurko A; Zakharenko S; Nerovjna R; Kljukina L; Erokhina O; Branovskaja M; Nikitina M; Grunberga V; Grunberg A; Juschenko A; Santopietro R; Cintorino M; Tosi P; Syrjänen S
Int J STD AIDS; 2008 Jan; 19(1):16-25. PubMed ID: 18275641
[TBL] [Abstract][Full Text] [Related]
19. Burning wood in the kitchen increases the risk of cervical neoplasia in HPV-infected women in Honduras.
Velema JP; Ferrera A; Figueroa M; Bulnes R; Toro LA; de Barahona O; Claros JM; Melchers WJ
Int J Cancer; 2002 Feb; 97(4):536-41. PubMed ID: 11802219
[TBL] [Abstract][Full Text] [Related]
20. [Prevalence of human papilloma virus and analysis of its risk factors in Daqing city, Heilongjiang province in 2010].
Yang L; Li N; Guo LW; Li Q; Cui H; Dai M
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Feb; 47(2):118-23. PubMed ID: 23719101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
